Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas

BACKGROUND: Oncogenic mutations in the KRAS gene are very common in human cancers, resulting in cells with well-characterized selective advantages. For more than three decades, the development of effective therapeutics to inhibit KRAS-driven tumorigenesis has proved a formidable challenge and KRAS w...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chenyue, Gao, Qiongmei, Wu, Zhengming, Lou, Weijuan, Li, Xiaoyan, Wang, Menghui, Wang, Nianhong, Li, Qingquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483799/
https://www.ncbi.nlm.nih.gov/pubmed/36115073
http://dx.doi.org/10.1016/j.tranon.2022.101540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483799/
https://www.ncbi.nlm.nih.gov/pubmed/36115073
http://dx.doi.org/10.1016/j.tranon.2022.101540

Ejemplares similares